Blueprint Medicines Corporation (BPMC)

93,00 +2,27 (+2,50%) Al cierre: 04:00PM EDT

Blueprint Medicines Corporation

45 Sidney Street
Cambridge, MA 02139
United States
617 374 7580
https://www.blueprintmedicines.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 655

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Ms. Kathryn Haviland	President, CEO & Director	1,17M	N/A	1976
Mr. Alexis A. Borisy A.M.	Co-Founder & Director	50k	N/A	1972
Mr. Michael Landsittel	Chief Financial Officer	785,36k	N/A	1972
Ms. Tracey L. McCain Esq.	Executive VP, Chief Legal & Compliance Officer and Secretary	764,9k	N/A	1968
Dr. Fouad Namouni M.D.	President of Research & Development	916,4k	N/A	1969
Ms. Ariel Hurley	Senior VP, Finance & Principal Accounting Officer	N/A	N/A	1974
Dr. Christopher K. Murray Ph.D.	Senior VP of Technical Operations and Chief Technical Operations & Quality Officer	338,37k	N/A	1964
Dr. Percy H. Carter M.B.A., Ph.D.	Chief Scientific Officer	761,15k	N/A	1971
Jenna Cohen	Senior Director & Head of Investor Relations	N/A	N/A	N/A
Ms. Debra Durso-Bumpus	Chief People Officer	N/A	N/A	1970

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Blueprint Medicines Corporation, a día 1 de abril de 2024, es 6. Las puntuaciones base son Auditoría: 2; Tablero: 8; Derechos de los accionistas: 7; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.